Therapeutic formulations for the treatment of beta-amyloid related diseases
OwnerFrancine Gervais, Francesco Belliniinventors
Life of this patent
Estimating the term…
Abstract
The method is used for preventing or treating an amyloid-β related disease in a subject. The method comprises administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formulation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formulation, or (ii) an immune system modulator that pi-events or inhibits amyloid-β fibril formulation.
Claims79
A method of preventing or treating an amyloid-β related disease in a subject, said method comprising administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
A method of preventing or treating an amyloid-β related disease in a subject, said method comprising administering to a subject in need thereof an effective amount of 3-amino-1-propanesulfonic acid, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
A pharmaceutical composition for treating a subject comprising a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
A pharmaceutical composition comprising an effective amount of 3-amino-1-propanesulfonic acid, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
A kit comprising a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
The use of a first agent and a second agent in the preparation of a pharmaceutical composition for the treatment or prevention of an amyloid-β disease, wherein said first agent prevents or treats amyloid-β related disease, and said second agent is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formation.
Dependencies are inferred from the claim text.